Friday, July 10, 2026

Drug profile · INN

levallorphan tartrate

levallorphan tartrate (LORFAN) is a kappa opioid receptor partial agonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — levallorphan tartrate
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

levallorphan tartrate (LORFAN) is a kappa opioid receptor partial agonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN levallorphan tartrate
Brand LORFAN
Mechanism Kappa opioid receptor partial agonist
Target Kappa-type opioid receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Kappa opioid receptor partial agonist

Primary target: Kappa-type opioid receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. buprenorphine Nervous system (N07)
  2. buprenorphine hydrochloride Mu opioid receptor agonist
  3. anileridine hydrochloride Kappa opioid receptor agonist
  4. anileridine phosphate Kappa opioid receptor agonist
  5. butorphanol tartrate Kappa opioid receptor partial agonist
  6. dezocine Kappa opioid receptor antagonist

Frequently asked questions

What is levallorphan tartrate?

levallorphan tartrate (LORFAN) is a kappa opioid receptor partial agonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for levallorphan tartrate?

LORFAN is a marketed brand name for levallorphan tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of levallorphan tartrate?

levallorphan tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.